➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: May 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for NOVA-22007

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug NOVA-22007?

NOVA-22007 is an investigational drug.

There have been 24 clinical trials for NOVA-22007. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2012.

The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetes Mellitus, Type 2, and Insulin Resistance. The leading clinical trial sponsors are Canadian Institutes of Health Research (CIHR), Nova Scotia Health Authority, and Canadian Network for Observational Drug Effect Studies, CNODES.

There are two US patents protecting this investigational drug and forty-six international patents.

Recent Clinical Trials for NOVA-22007
Trial of Maintenance With Niraparib- Uterine Serous CarcinomaTesaro, Inc.Phase 2
Trial of Maintenance With Niraparib- Uterine Serous CarcinomaNorthwell HealthPhase 2
Lisdexamfetamine for Adults With Bulimia NervosaNova Scotia Health AuthorityPhase 2

See all NOVA-22007 clinical trials

Clinical Trial Summary for NOVA-22007

Top disease conditions for NOVA-22007
Top clinical trial sponsors for NOVA-22007

See all NOVA-22007 clinical trials

US Patents for NOVA-22007

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
NOVA-22007   Start Trial Methods for determining risk of chronic lung allograft dysfunction (CLAD) and subtypes thereof University Health Network (Toronto, CA)   Start Trial
NOVA-22007   Start Trial Targeted poorly water-soluble drug delivery system, method of preparing the same, and pharmaceutical composition including the same SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR)   Start Trial
NOVA-22007   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
NOVA-22007   Start Trial Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN)   Start Trial
NOVA-22007   Start Trial Salts of an epidermal growth factor receptor kinase inhibitor Celgene CAR LLC (Pembroke, BM)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for NOVA-22007

Drugname Country Document Number Estimated Expiration Related US Patent
NOVA-22007 Canada 2938893 2033-02-20   Start Trial
NOVA-22007 European Patent Office 2959017 2033-02-20   Start Trial
NOVA-22007 World Intellectual Property Organization (WIPO) 2014127463 2033-02-20   Start Trial
NOVA-22007 European Patent Office 2896401 2032-09-12   Start Trial
NOVA-22007 South Korea 101493930 2032-09-12   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.